Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAT-DX1-NP
- Development stage
- Preclinical
- Lead developer
- Patrys
- Modality
- Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
PAT-DX1-NP is a nanoparticle-conjugated therapeutic platform developed by Patrys Limited. It utilizes PAT-DX1, a humanized, cell-penetrating antibody derived from the lupus autoantibody Deoxymab 3E10, to deliver therapeutic payloads specifically to cancer cells. The PAT-DX1 component targets nuclear DNA at sites of damage and inhibits the DNA damage repair (DDR) process. By conjugating this antibody to nanoparticles, the platform can transport various agents, such as chemotherapeutic agents, directly into the nuclei of malignant cells. PAT-DX1-NP is designed to exploit DNA repair deficiencies in tumors and is capable of crossing the blood-brain barrier, making it a candidate for treating primary brain cancers like glioblastoma as well as metastatic brain tumors.
- Other names
- PAT-DX1 nanoparticle conjugatePAT-DX-1 nanoparticle conjugatePAT-DX 1 nanoparticle conjugate
02
Targets
ENT2 (Equilibrative nucleoside transporter 2)eDNA (Extracellular DNA)
Beyond the preview
Go deeper on PAT-DX1-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAT-DX1-NP.